Type of information: Company acquisition
Acquired company: Viratherapeutics (Austria)
Acquiring company: Boehringer Ingelheim (Germany)
Amount: €210 million
- • On September 13, 2018, Boehringer Ingelheim announced that it has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies. The total transaction value of €210 million is based on an option and share purchase agreement signed between the companies in August 2016.
- ViraTherapeutics is a biopharmaceutical company specializing in the development of oncolytic viral therapies. The company developed the lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP)), which is being investigated alone and in combination with other therapies. Boehringer Ingelheim and ViraTherapeutics are working to develop a next generation oncolytic viral therapy platform. The lead investigational candidate leveraging the platform, VSV-GP, has shown promising results in pre-clinical models, especially in combination with key immune modulatory principles Boehringer Ingelheim is developing. Using a dual approach for potential treatment options, specifically combining immuno-oncology approaches with tumor cell-directed treatments, is central to Boehringer Ingelheim’s cancer immunology research strategy. Oncolytic virus-based therapies are consistent with and complement that strategy.
Related: Cancer - Oncology